Summary
The project aims to identify non-invasive biomarkers for pre-symptomatic Alzheimer's disease (AD) using electrophysiological methods (EEG, ECG) during cognitive challenges, benchmarked against established amyloid/tau CSF biomarkers.
Cognitive challenge to reveal systemic neurophysiology biomarkers in pre-symptomatic Alzheimer’s disease
US · IL
NIH
grant
awarded
#nih-5R01AG063857-05
What they want
The project addresses the knowledge gap in early detection and prediction of AD symptom onset. It hypothesizes that measurements of the conscious executive function, subliminal processing, and autonomic regulation (CSA system) during cognitive challenge will provide robust biomarkers for pre-symptomatic AD. Specific Aims include testing this hypothesis in a new cohort and evaluating the ability of CSA biomarkers to identify individuals with pathological CSF ratios (CH-PATs) and predict cognitive decline in a 2-year longitudinal study. The goal is to provide multiple novel translational biomarkers that are non-invasive and benchmarked to established CSF biomarkers.
Deliverables
- multiple novel translational biomarkers to characterize pre-symptomatic AD
Technical requirements
- non-invasive electrophysiological methods (EEG and ECG)
- cognitive challenge
- CSF Aß42/Tau ratio cutoff
- multi-domain, neuropsychometric battery
